BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21194020)

  • 1. Monitoring duchenne muscular dystrophy gene therapy with epitope-specific monoclonal antibodies.
    Morris G; Man Nt; Sewry CA
    Methods Mol Biol; 2011; 709():39-61. PubMed ID: 21194020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies for clinical trials of Duchenne muscular dystrophy therapy.
    Le TL; Nguyen TM; Morris GE
    Neuromuscul Disord; 2014 Mar; 24(3):195-200. PubMed ID: 24361045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of genetic deletions in Becker muscular dystrophy using monoclonal antibodies against a deletion-prone region of dystrophin.
    Le Thiet Thanh ; Nguyen Thi Man ; Hori S; Sewry CA; Dubowitz V; Morris GE
    Am J Med Genet; 1995 Aug; 58(2):177-86. PubMed ID: 8533812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy.
    Ferrer A; Wells KE; Wells DJ
    Gene Ther; 2000 Sep; 7(17):1439-46. PubMed ID: 11001363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for muscle disease.
    Miyagoe-Suzuki Y; Takeda S
    Exp Cell Res; 2010 Nov; 316(18):3087-92. PubMed ID: 20580709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
    Zhang C; Feng HY; Huang SL; Fang JP; Xiao LL; Yao XL; Chen C; Ye X; Zeng Y; Lu XL; Wen JM; Zhang WX; Li Z; Feng SW; Xu HG; Huang K; Zhou DH; Chen W; Xie YM; Xi J; Zhang M; Li Y; Liu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Aug; 22(4):399-405. PubMed ID: 16086277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress toward gene therapy of Duchenne muscular dystrophy.
    Hartigan-O'Connor D; Chamberlain JS
    Semin Neurol; 1999; 19(3):323-32. PubMed ID: 12194388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xp21 dystrophin and 6q dystrophin-related protein. Comparative immunolocalization using multiple antibodies.
    Voit T; Haas K; Léger JO; Pons F; Léger JJ
    Am J Pathol; 1991 Nov; 139(5):969-76. PubMed ID: 1951635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
    Popplewell LJ; Graham IR; Malerba A; Dickson G
    Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dystrophin as a diagnostic marker in Duchenne and Becker muscular dystrophy. Correlation of immunofluorescence and western blot.
    Voit T; Stuettgen P; Cremer M; Goebel HH
    Neuropediatrics; 1991 Aug; 22(3):152-62. PubMed ID: 1944822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
    Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy.
    Harper SQ; Hauser MA; DelloRusso C; Duan D; Crawford RW; Phelps SF; Harper HA; Robinson AS; Engelhardt JF; Brooks SV; Chamberlain JS
    Nat Med; 2002 Mar; 8(3):253-61. PubMed ID: 11875496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells.
    Skuk D; Goulet M; Roy B; Chapdelaine P; Bouchard JP; Roy R; Dugré FJ; Sylvain M; Lachance JG; Deschênes L; Senay H; Tremblay JP
    J Neuropathol Exp Neurol; 2006 Apr; 65(4):371-86. PubMed ID: 16691118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
    Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
    Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy.
    Athanasopoulos T; Foster H; Foster K; Dickson G
    Methods Mol Biol; 2011; 709():21-37. PubMed ID: 21194019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duchenne and Becker muscular dystrophy: from gene diagnosis to molecular therapy.
    Matsuo M
    IUBMB Life; 2002 Mar; 53(3):147-52. PubMed ID: 12102170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splicing intervention for Duchenne muscular dystrophy.
    McClorey G; Fletcher S; Wilton S
    Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Specificity of the dystrophin immunohistochemical technique in muscular dystrophy].
    Colomer Oferil J; Vila Torres J; Huezo Montoya C
    Neurologia; 1993 May; 8(5):112-5. PubMed ID: 8507503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.